We’re on a mission to improve the standard of care worldwide. For over 30 years, we’ve developed transformative therapies for liver diseases, HIV, cardiopulmonary diseases, and oncology. With your help, we believe we can do it again for inflammatory diseases.
More than 300 million people worldwide are living with chronic hepatitis B or C infection, making viral hepatitis many times more common than HIV.1
Gilead has developed breakthrough medicines that can cure patients of hepatitis C virus (HCV) infection, regardless of the virus genotype or cirrhosis status. We’ve also developed medications that help people living with hepatitis B virus (HBV) infection manage their condition, and we continue to investigate new therapies that may allow patients to potentially control or eliminate HBV without having to endure a lifetime of treatment.
Beyond therapeutic advancement, Gilead works to expand hepatitis screening for at-risk individuals and increase access to our medicines around the world. We actively support the efforts of governments and partner with other groups who have declared their commitment to the World Health Organization (WHO) goal of eliminating viral hepatitis globally by 2030.2
Through our antiretroviral therapies, we’ve helped transform HIV infection from a fatal disease to a manageable condition for many.3
We’re also at the forefront of pre-exposure prophylaxis (PrEP), an approach that involves the use of antiretroviral medication to reduce the chances of sexually acquiring HIV-1 infection in HIV-negative individuals at risk. And we continue to research a cure for HIV that will suppress or eliminate the virus without continuous antiretroviral therapy.
Kite, a Gilead company, is pioneering CAR T-cell therapy to help treat patients with certain hematologic cancers. This innovative approach re-engineers a patient’s white blood cells to transform their immune system into their own cancer-fighting therapy.
130 countries
Patients in over 130 countries reached with our treatment programs, in collaboration with international and local partners on the ground4
27 marketed drugs
27 marketed drugs and an active R&D program5
4 million
More than 4 million people worldwide have received Gilead-based curative HCV regimens6
$50 million
Gilead has committed $50M to support 79 HCV elimination projects worldwide through LEGA-C7
12.6 million
An estimated 12.6 million people who live with HIV in resource-challenged countries receive a Gilead-based treatment every day6
2.4 million
2.4 million bottles of Gilead HIV prevention medication to be donated to CDC annually for uninsured Americans at risk of HIV7
CAR, chimeric antigen receptor; CDC, Centers for Disease Control and Prevention; LEGA-C, Local Elimination Programs Leading to Global Action in HCV; R&D, research and development.
References: 1. Gilead Life Sciences. https://www.gilead.com/purpose/medication-access/global-access/viral-hepatitis. Accessed April 1, 2020. 2. Gilead Life Sciences. https://www.gilead.com/purpose/advancing-global-health/hcvelimination. Accessed April 1, 2020. 3. US Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/Ivguidelines/AdultandAdolescentGL.pdf. Updated December 18, 2019. Accessed January 24, 2020. 4. Data on file. Gilead Sciences, Inc.; 2018. 5. Gilead Life Sciences. https://www.gilead.com/science-and-medicine/medicines. Accessed April 1, 2020. 6. Data on file. Gilead Sciences, Inc.; 2020. 7. Data on file. Gilead Sciences, Inc.; 2019.
GILEAD and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or one of its related companies.
© 2020 Gilead Sciences, Inc. All rights reserved.
UNBP5968 10/20
